Drug Trial Radar · NCT01130272
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
Last checked: Nov 20, 2026Latest source record: Oct 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
807
Actual
Start
Apr 28, 2010
Primary completion
Jul 14, 2011
Study completion Jul 14, 2011
Sponsor
- Lead sponsor
- Furiex Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
Conditions
- Irritable Bowel Syndrome
Interventions
EluxadolineDrug
Tablets, orally, twice daily.
PlaceboDrug
Matching placebo oral tablets twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4Time frame: Baseline (Week prior to Randomization) to Week 4
- Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 12Time frame: Baseline (Week prior to Randomization) to Week 12
Locations
288 sites in 1 country. Site status is shown where the registry gives one.
Furiex Research Site
Anniston, Alabama
Furiex Research Site
Birmingham, Alabama
Furiex Research Site
Birmingham, Alabama
Furiex Research Site
Dothan, Alabama
Furiex Research Site
Huntsville, Alabama
Furiex Research Site
Huntsville, Alabama
Furiex Research Site
Mobile, Alabama
Furiex Research Site
Montgomery, Alabama
Furiex Research Site
Pell City, Alabama
Furiex Research Site
Chandler, Arizona
Furiex Research Site
Glendale, Arizona
Furiex Research Site
Mesa, Arizona
Furiex Research Site
Phoenix, Arizona
Furiex Research Site
Phoenix, Arizona
Furiex Research Site
Phoenix, Arizona
Furiex Research Site
Tempe, Arizona
Furiex Research Site
Tempe, Arizona
Furiex Research Site
Tucson, Arizona
Furiex Research Site
Tucson, Arizona
Furiex Research Site
Jonesboro, Arkansas
Furiex Research Site
Little Rock, Arkansas
Furiex Research Site
Searcy, Arkansas
Furiex Research Site
Sherwood, Arkansas
Furiex Research Site
Aliso Viejo, California
Furiex Research Site
Anaheim, California
Furiex Research Site
Azusa, California
Furiex Research Site
Burbank, California
Furiex Research Site
Carlsbad, California
Furiex Research Site
Encinitas, California
Furiex Research Site
Garden Grove, California
Furiex Research Site
Garden Grove, California
Furiex Research Site
Inglewood, California
Furiex Research Site
Laguna Hills, California
Furiex Research Site
Long Beach, California
Furiex Research Site
Los Angeles, California
Furiex Research Site
Los Angeles, California
Furiex Research Site
Murrieta, California
Furiex Research Site
Oakland, California
Furiex Research Site
Orange, California
Furiex Research Site
Sacramento, California
Showing 40 of 288 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.